Predicting Risk Versus Predicting Potential Survival Benefit Using I-123-mIBG Imaging in Patients With Systolic Dysfunction Eligible for Implantable Cardiac Defibrillator Implantation Analysis of Data From the Prospective ADMIRE-HF Study

摘要

Background Cardiac I-123-metaiodobenzylguanidine (I-123-mIBG) imaging improves prognostication in patients with left ventricular (LV) dysfunction. Whether I-123-mIBG can identify optimal candidates for implantable cardiac defibrillator (ICD) placement is unclear. We examined whether I-123-mIBG enhances risk assessment and identifies patients with enhanced survival with ICD in a patient cohort with reduced LV function who were candidates for ICD implantation.